Triangle Business Journal -- Global sales of Trimeris’ AIDS drug, Fuzeon, fell by 39 percent in the fourth quarter, continuing the treatment’s downward trend. Trimeris (Nasdaq: TRMS), based in Durham, says worldwide net sales of the treatment were $40.5 million, down from $66.5 million in the fourth quarter of 2007.
